T Cell News and Research

Latest T Cell News and Research

OICR funding to help five research projects take the next step toward advancing cancer care

Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for Cancer Research (OICR).

11 Aug 2022

Gut microbial and immune parameters linked to heterogeneous inter-personal COVID-19 vaccine-triggered immunity

A new study identified the gut microbial and immune variables linked to heterogeneous messenger ribonucleic acid (mRNA) COVID-19 vaccine responses between individuals.

11 Aug 2022

B-cell responses to COVID mRNA vaccine are enhanced by a 16-week interval between doses

Researchers assess the impact of extending the interval between primary and booster COVID-19 vaccine doses.

9 Aug 2022

Higher doses of CAR-T therapy achieve better survival rates for young patients with hard-to-treat B-ALL

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.

8 Aug 2022

Gut microbiota-derived metabolites offer protection against SARS-CoV-2

A new study investigated how the gut microbiome confers immunity to mammalian hosts against SARS-CoV-2 intranasal infection by generating short-chain fatty acids.

5 Aug 2022

A combined influenza and COVID-19 mRNA vaccine

A combined mRNA vaccine is capable of inducing broad and durable protection against co-infection with SARS-CoV-2 and IAV,

3 Aug 2022

Hybrid immunity retained six months after SARS-CoV-2 exposure

Scientists hypothesize that lower death rates in COVID-19 patients may be due to hybrid immunity, as well as the reduced severity of Omicron infections.

3 Aug 2022

Memory B and T cell responses to the SARS-CoV-2 spike protein before and after the third BNT162b2 booster

Researchers evaluated memory B and T cell responses to SARS-CoV-2 before and after the third dose of the BNT162b2 vaccine.

3 Aug 2022

Shear-thinning biomaterial-based minimally invasive strategy for delivery of targeted immunotherapy

Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed and optimized a minimally invasive method for more targeted, efficient, and sustained delivery of immunotherapeutic treatments for cancer.

2 Aug 2022

Highly specialized T cells remain in blood 20 months after COVID-19

researchers analyze T-cell reactivity following recovery from COVID-19.

27 Jul 2022

The nose key to winning the war against COVID-19

researchers assess the respiratory mucosal immunity elicited by COVID-19 vaccination.

27 Jul 2022

Innovative technology reveals new insights into cellular reservoirs of HIV

In a presentation today at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research. NIAID is part of the National Institutes of Health.

27 Jul 2022